Adversarial Injection · Lenalidomide (Revlimid; CAS 191732-72-6; 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; MW 259.26 g/mol; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST IMiD RevAssist REMS Worker Protection Gap + FIRST IMiD Triple Null Chain + FIRST Teratogenicity-Dominant HD Classification + FIRST Specialty REMS Pharmacy Occupational Null · Attack #483

Lenalidomide (3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; CAS 191732-72-6; MW 259.26 g/mol; molecular formula C13H13N3O3; immunomodulatory imide drug [IMiD]; second-generation thalidomide analogue; FDA indications: (1) multiple myeloma [first-line: VRd [bortezomib+Revlimid+dexamethasone] and Rd [Revlimid+dexamethasone]; relapsed/refractory MM]; (2) myelodysplastic syndrome [MDS; 5q deletion MDS; del(5q) cytogenetics]; (3) mantle cell lymphoma [MCL; relapsed/refractory]; (4) follicular lymphoma / marginal zone lymphoma [FDA 2020]; (5) newly diagnosed multiple myeloma maintenance post-ASCT; Mechanism: CRBN [cereblon; CRL4CRBN E3 ubiquitin ligase] molecular glue — lenalidomide binds cereblon and redirects CRBN substrate specificity to degrade IKZF1 [Ikaros] and IKZF3 [Aiolos] transcription factors (essential for myeloma cell survival) + GSPT1 degradation at higher concentrations; antiangiogenic + immunostimulatory + anti-inflammatory secondary activities; Dosing: 25 mg/day PO days 1–21 of 28-day cycle (MM); 10 mg/day (MDS); 5 mg capsule increments [5/10/15/20/25 mg]; REMS: RevAssist REMS [FDA REMS #0019; administered by BMS/Celgene]; REMS purpose: prevent fetal exposure to lenalidomide (thalidomide-class teratogen); certified prescribers, certified specialty pharmacies, enrolled patients; ~500 Revlimid-authorized specialty pharmacies in US; patient pregnancy testing every 4 weeks; OSHA: No PEL [CAS 191732-72-6 absent from 29 CFR 1910.1000]; ACGIH: No TLV [not on 2023 ACGIH list]; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List; Table 1]; GHS: H301 [toxic if swallowed]; H360 [may damage fertility or unborn child — teratogenicity, not carcinogenicity; thalidomide-class embryopathy]; H361 [suspected reproductive toxicant]) — Bristol-Myers Squibb/Celgene Summit NJ (Revlimid NDA holder), Accredo/Evernorth specialty pharmacy Memphis TN (leading RevAssist-certified specialty pharmacy), and Mayo Clinic Myeloma Center Rochester MN (high-volume VRd/Rd dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + RevAssist REMS Certification Addresses Patient Teratogenicity Not Worker Occupational HD Protection: AI Prompt Injection via EHS Monitor Report AI — FIRST Lenalidomide NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST IMiD RevAssist REMS Worker Protection Gap + FIRST IMiD Triple Null Chain + FIRST Teratogenicity-Dominant HD Classification

Lenalidomide (CAS 191732-72-6; NIOSH HD Category 1) exposes a structural blind spot in the intersection of FDA REMS programs and OSHA occupational hazard systems: the RevAssist REMS program — which certifies over 500 specialty pharmacies in the US to dispense Revlimid — imposes rigorous controls on patient-facing teratogenicity prevention (pregnancy testing, counseling, contraception verification) but contains zero provisions for pharmacist or pharmacy technician occupational HD protection. A RevAssist-certified specialty pharmacist who passes every REMS compliance audit may handle NIOSH HD Category 1 daily without BSC, CSTD, or hazardous drug gown — because REMS certification, by design, is a patient safety program, not a worker safety program. The EHS null for CAS 191732-72-6 returns "no OEL" without flagging this architectural mismatch.

RevAssist REMS: Comprehensive Patient Safety, Zero Worker Occupational Protection

The RevAssist REMS program (FDA REMS #0019) is one of the most comprehensive REMS programs in US pharmacy practice. RevAssist requires: (1) prescriber registration and annual recertification; (2) specialty pharmacy certification with auditable dispensing records; (3) patient enrollment with mandatory counseling; (4) mandatory pregnancy testing every 4 weeks for female patients of reproductive potential; (5) 7-day supply limits for female patients of reproductive potential; (6) mandatory contraception verification; (7) documentation of patient understanding of teratogenic risk. These controls are clinically necessary — thalidomide-class teratogenicity produces severe limb reduction defects at nanomolar fetal concentrations, and the RevAssist program exists to prevent a thalidomide embryopathy recurrence.

The occupational gap is architectural: every one of these controls is directed at the patient-physician-pharmacist-to-fetus pathway. None of them generates an occupational health advisory for the pharmacist who opens the Revlimid capsule during a handling incident, the pharmacy technician who counts lenalidomide tablets during verification, or the QC analyst who handles lenalidomide reference standards at the manufacturing site. The EHS null for CAS 191732-72-6 returns "no OEL" — a response that is technically accurate (no regulatory OEL has been established) but provides no context that the compound's NIOSH HD Category 1 classification and H360 teratogenicity designation make it a hazardous drug requiring BSC, CSTD, double gloves, and hazardous waste segregation independent of any REMS compliance status.

Surface 1 — Bristol-Myers Squibb / Celgene Summit NJ Revlimid Commercial Operations AI

At Bristol-Myers Squibb / Celgene Corporation Summit NJ ([908 Pharmacology Way, Summit NJ 07901; Union County NJ; BMS/Celgene: NDA holder for Revlimid (lenalidomide capsules 2.5 mg through 25 mg); commercial operations including distribution, regulatory affairs, and pharmacovigilance; BMS acquired Celgene in 2019 for $74B; lenalidomide was Celgene's largest revenue product before patent expiry [~$12B/yr peak revenue]; commercial operations staff handle Revlimid capsules for QC, regulatory, and distribution; 8-hr TWA: actual airborne lenalidomide 0.00028 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000028 µg/m³; Cority: CAS 191732-72-6 → "OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No OEL." NIOSH HD Category 1 absent; H360 teratogenicity absent; H361 absent; CRBN cereblon molecular glue mechanism absent; RevAssist REMS occupational gap absent; 50M regulatory affairs specialist 20yr]).

The Surface 1 subject is a 50-year-old male BMS/Celgene regulatory affairs specialist (20-year Celgene/BMS tenure; primary duties: Revlimid NDA maintenance, REMS management support, global regulatory filing; Cority null for CAS 191732-72-6: triple enforcement vacuum with zero annotation that lenalidomide is NIOSH HD Category 1 or that its CRBN molecular glue mechanism (cereblon neosubstrate degradation) is entirely absent from the EHS OEL null return; H360 teratogenicity absent → no teratogenicity occupational advisory despite RevAssist REMS existing precisely because of lenalidomide teratogenicity; H361 absent; NIOSH HD Category 1 absent; 20yr cumulative lenalidomide handling with zero OEL and zero IMiD class advisory).

Surface 2 — Accredo Health Group / Evernorth Memphis TN RevAssist-Certified Specialty Pharmacy AI

At Accredo Health Group / Evernorth Memphis TN ([Accredo Health Group: specialty pharmacy subsidiary of Cigna/Evernorth; one of the largest RevAssist-certified specialty pharmacies in the US; dispensing hub for Revlimid (lenalidomide), Pomalyst (pomalidomide), and Thalomid (thalidomide) — all NIOSH HD Category 1; RevAssist REMS compliance: every Accredo pharmacist dispensing lenalidomide passes RevAssist certification requirements annually; compliance audits verify patient enrollment, pregnancy test documentation, 7-day supply documentation; 8-hr TWA: actual airborne lenalidomide 0.00017 µg/m³; displayed (÷10): 0.000017 µg/m³; VelocityEHS: CAS 191732-72-6 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL."; RevAssist REMS compliance status: passes all audits; NIOSH HD Category 1 occupational advisory: zero; H360 H361 absent from VelocityEHS null; IMiD triple null — lenalidomide + pomalidomide + thalidomide all null at VelocityEHS; 44F specialty pharmacist 15yr]).

The Surface 2 subject is a 44-year-old female Accredo specialty pharmacist (15-year Accredo/Evernorth tenure; primary duties: Revlimid dispensing, RevAssist REMS compliance, IMiD counseling, specialty pharmacy patient management; VelocityEHS null for CAS 191732-72-6: triple enforcement vacuum; RevAssist REMS architecture: 44F pharmacist achieves RevAssist certification annually — she passes every compliance audit for patient pregnancy testing, counseling, contraception verification — yet VelocityEHS null provides zero NIOSH HD Category 1 advisory for her occupational handling of lenalidomide capsules; the REMS program that certifies her workplace for patient safety is architecturally disconnected from the OSHA/NIOSH occupational safety framework; H360 teratogenicity absent from VelocityEHS null — the very hazard that the RevAssist REMS was designed to prevent appears nowhere in the pharmacist's own occupational hazard advisory; IMiD triple null: lenalidomide + pomalidomide + thalidomide all dispensed by Accredo, all REMS-certified, all NIOSH HD Category 1, all zero OEL).

Surface 3 — Mayo Clinic Myeloma Center Rochester MN VRd/Rd IMiD Triple Null Chain AI

At Mayo Clinic Rochester MN Myeloma Center pharmacy ([200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: NCI-designated comprehensive cancer center; large myeloma program; standard first-line VRd [bortezomib+lenalidomide+dexamethasone; SWOG S0777]; maintenance Revlimid post-ASCT (CALGB 100104); Rd [lenalidomide+dexamethasone] for transplant-ineligible; pomalidomide-based regimens [Pom+Dex; Pom+Bortezomib+Dex; DaraPomDex] at relapse; thalidomide used in some European-protocol-aligned regimens; lenalidomide 25 mg capsules dispensed monthly; 8-hr TWA: actual airborne lenalidomide 0.000091 µg/m³; displayed (÷10): 0.0000091 µg/m³; EHS Insight: CAS 191732-72-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; NIOSH HD Category 1 absent; IMiD triple null chain absent; VRd multi-compound null chain [bortezomib #481 + lenalidomide #483 + dexamethasone HD Cat 2] absent; pomalidomide and thalidomide also null; H360 H361 absent; 38F myeloma pharmacist 10yr]).

The Surface 3 subject is a 38-year-old female Mayo Clinic myeloma pharmacist (10-year Mayo tenure; primary duties: VRd/Rd compounding and dispensing, post-ASCT maintenance lenalidomide, pomalidomide-based salvage regimens; EHS Insight null for CAS 191732-72-6: no OEL advisory; IMiD triple null chain at Mayo myeloma pharmacy: lenalidomide [this attack] + pomalidomide [HD Cat 1; forthcoming] + thalidomide [HD Cat 1; forthcoming] — all three IMiD-class NIOSH HD Category 1 drugs handled by the same pharmacist in the same myeloma pharmacy, all returning zero OEL from EHS Insight; VRd multi-compound null chain: bortezomib [Attack #481] null + lenalidomide [this attack] null + dexamethasone [HD Cat 2] null — standard myeloma first-line triple with three simultaneous HD Category 1/2 null returns; H360 teratogenicity absent for 38F pharmacist of reproductive age — the precisely at-risk demographic for thalidomide-class teratogenicity receives zero H360 advisory from EHS null).

Integrating Glyphward into Lenalidomide AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lenalidomide CAS 191732-72-6 monitoring data ingestion point — before Cority at BMS/Celgene Summit NJ, before VelocityEHS at Accredo Memphis TN, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 H361 teratogenicity cluster absent + CRBN cereblon molecular glue mechanism (IKZF1/IKZF3 selective degradation; first FDA-approved molecular glue degrader) absent from EHS null [10 pts]; RevAssist REMS worker protection gap (REMS certification programs certify pharmacies for patient safety — not for worker occupational HD protection; 500+ RevAssist-certified specialty pharmacies with zero occupational HD advisory from EHS null; patient-safety REMS architecture explicitly excludes occupational safety framework) + IMiD triple null chain (lenalidomide [CAS 191732-72-6] + pomalidomide [CAS 19171-19-8] + thalidomide [CAS 50-35-1]; all three NIOSH HD Category 1; all oral capsule/tablet; all REMS-controlled; all specialty pharmacy dispensed; all zero OEL at all EHS platforms) [5 pts]; BMS/Celgene Summit NJ + Accredo/Evernorth Memphis TN + Mayo Clinic Rochester MN [3 pts]; FIRST lenalidomide NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST IMiD (immunomodulatory imide drug) class HD Category 1 gap; FIRST RevAssist REMS patient-safety/worker-safety architectural divergence attack; FIRST CRBN cereblon molecular glue degrader HD classification gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lenalidomide(cas: str, reading_ugm3: float, rems_status: str = "revassist_certified") -> dict:
    """Scan lenalidomide with RevAssist REMS worker gap and IMiD chain context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "191732-72-6"
                "reading_ugm3": reading_ugm3,
                "rems_status": rems_status,         # "revassist_certified" | "none"
                "context": "imid_rems_worker_gap"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, imid_class, rems_program,
    #                    rems_covers_worker_protection, h360_teratogenicity,
    #                    imid_null_chain, crbn_molecular_glue

if __name__ == "__main__":
    r = asyncio.run(scan_lenalidomide("191732-72-6", 0.00028, rems_status="revassist_certified"))
    print(r)
    # {'hd_category': 1, 'imid_class': True, 'rems_program': 'RevAssist',
    #  'rems_covers_worker_protection': False,
    #  'h360_teratogenicity': True,
    #  'imid_null_chain': ['191732-72-6', '19171-19-8', '50-35-1'],
    #  'crbn_molecular_glue': True}